The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
Claims What is claimed is: 1. Compounds of the general formula (I) in which R.sup.1 represents a radical of the formula ##STR44## in which R.sup.3 and R.sup.3' together with the phenyl double bond form a 5-membered, saturated, partially unsaturated or aromatic heterocycle which contains one or two O atoms and where all of the ring systems listed above are optionally substituted, optionally geminally, by one or more identical or different substituents selected from the group consisting of: halogen, carboxyl, hydroxyl, phenyl, (C.sub.1 -C.sub.6)-alkoxy, (C.sub.1 -C.sub.6)-alkoxycarbonyl, (C.sub.1 -C.sub.8)-alkyl, which for its part may be substituted by halogen, (C.sub.1 -C.sub.6)-alkylsulphonyloxy, azide, amino, mono(C.sub.1 -C.sub.6)-alkylamino, di(C.sub.1 -C.sub.6)-alkylamino or hydroxyl, a group of the formula --(CO).sub.b --NR.sup.4 R.sup.5, in which b represents a number 0 or 1, R.sup.4 and R.sup.5 are identical or different and independently of one another represent hydrogen, phenyl, (C.sub.1 -C.sub.6)-acyl, cyclo(C.sub.4 -C.sub.7)-acyl benzoyl or (C.sub.1 -C.sub.6)-alkyl, which is optionally substituted by amino, mono(C.sub.1 -C.sub.6)-alkylamino, di(C.sub.1 -C.sub.6)-alkylamino, or R.sup.4 and R.sup.5 together with the nitrogen atom form a 5- or 6-membered saturated heterocycle which may optionally contain one or more further heteroatom(s) from the group consisting of S and O and/or one or more radical(s) of the formula --NR.sup.8, R.sup.8 represents hydrogen, (C.sub.1 -C.sub.6)-alkyl or (C.sub.1 -C.sub.6)-acyl, and a group of the formula --NR.sup.6 --SO.sub.2 --R.sup.7 in which R.sup.6 represents hydrogen, phenyl, (C.sub.1 -C.sub.6)-alkyl or (C.sub.1 -C.sub.6)-acyl, R.sup.7 represents phenyl or (C.sub.1 -C.sub.6)-alkyl, and a radical of the formula ##STR45## in which c represents a number 1, 2, 3, 4, 5 or 6, R.sup.9 and R.sup.10 are identical or different and represent hydrogen or (C.sub.1 -C.sub.6)-alkyl, T represents a radical of the formula --(CH.sub.2).sub.d --, in which d represents a number 1, 2, 3, 4, 5 or 6, or T represents a moiety of an amino acid radical of the formula ##STR46## in which R.sup.13 and R.sup.14 are identical or different and represent hydrogen or methyl, or R.sup.13 represents hydrogen or methyl and R.sup.14 represents (C.sub.3 -C.sub.8)-cycloalkyl or (C.sub.6 -C.sub.10)-aryl or hydrogen, or (C.sub.1 -C.sub.8)-alkyl, where the (C.sub.1 -C.sub.8)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula --NR.sup.15 R.sup.16 or --NR.sup.17 --OC--, in which R.sup.15 and R.sup.16 independently of one another represent hydrogen, (C.sub.1 -C.sub.8)-alkyl or phenyl and R.sup.17 represents hydroxyl, benzyloxy, (C.sub.1 -C.sub.8)-alkoxy or the group --NR.sup.15 R.sup.16 listed above, or the (C.sub.1 -C.sub.8)-alkyl is optionally substituted by (C3-C6)-cycloalkyl or phenyl, which for its part is substituted by hydroxyl, halogen or (C.sub.1 -C.sub.6)-alkoxy or amino, or the (C.sub.1 -C.sub.8)-alkyl is optionally substituted by imidazolyl or indolyl, in which the corresponding --NH functions are optionally protected by (C.sub.1 -C.sub.6)-alkyl or by an amino protective group, R.sup.11 and R.sup.12 are identical or different and represent hydrogen, (C.sub.1 -C.sub.6)-alkyl or a typical amino protective group, or R.sup.11 and R.sup.12 together with the nitrogen atom form a 5- to 6-membered saturated heterocycle, which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula --NR.sup.18, in which R.sup.18 represents hydrogen, (C.sub.1 -C.sub.6)-alkyl or phenyl, A and E represent bonds, D represents an oxygen or sulfur atom G represents doubly attached (C.sub.6 -C.sub.10)-aryl, which is optionally substituted by one or more identical or different substituents selected from the group consisting of: hydroxyl, trifluoromethyl, carboxyl, halogen, (C.sub.1 -C.sub.6)-alkyl, hydroxy(C.sub.1 -C.sub.6)-alkyl, (C.sub.1 -C.sub.6)-alkoxy, (C.sub.1 -C.sub.6)-alkoxycarboayl, and groups of the formulae --CO--O--(CH.sub.2).sub.f --NR.sup.20 R.sup.21, --NR.sup.22 --SO.sub.2 R.sup.23, --(CH.sub.2).sub.g --(CO).sub.h --NR.sup.24 R.sup.25 and --OR.sup.26, in which f represents a number 1, 2, 3 or 4, g and h are identical or different and represent a number 0 or 1, R.sup.20 and R.sup.21 have the meaning of R.sup.4 and R.sup.5 given above and are identical to or different from this meaning, R.sup.22 has the meaning of R.sup.6 given above and is identical to or different from this meaning, R.sup.23 has the meaning of R.sup.7 given above and is identical to or different from this meaning, R.sup.24 and R.sup.25 have the meaning of R.sup.4 and R.sup.5 given above and are identical to or different from this meaning, or independently of one another represent a radical of the formula and pharmaceutically acceptable salts thereof. 2. Compounds of the general formula (I) according to claim 1, R.sup.1 represents a radical of the formula ##STR49## and where the ring systems listed above are optionally substituted, optionally geminally, by one or more identical or different substituents selected from the group consisting of: alkoxycarbonyl or (C.sub.1 -C.sub.6)-alkyl, which for its part may be substituted by fluorine, chlorine or hydroxyl, and a radical of the formula ##STR50## in which c represents a number 1, 2, 3, 4, 5 or 6, R.sup.9 and R.sup.10 are identical or different and represent hydrogen or (C.sub.1 -C.sub.6)-alkyl, T represents a radical of the formula --(CH.sub.2).sub.d --, in which d represents a number 1, 2, 3, 4, 5 or 6, or T represents a moiety of an amino acid radical of the formula ##STR51## in which R.sup.13 and R.sup.14 are identical or different and represent hydrogen or (C.sub.1 -C.sub.6)-alkyl, or R.sup.13 represents hydrogen or methyl and R.sup.14 represents cyclopropyl, cyclopentyl, cyclohexyl, phenyl or hydrogen, or represents (C.sub.1 -C.sub.6)-alkyl, where the (C.sub.1 -C.sub.6)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula and pharmaceutically acceptable salts thereof. 3. Compounds of the general formula (I), according to claim 1 in which R.sup.1 represents a radical of the formula ##STR53## and where the ring systems listed above are optionally substituted by one or more identical or different substituents selected from the group consisting of: chlorine, fluorine, hydroxyl, (C.sub.1 -C.sub.3)-alkoxy or (C.sub.1 -C.sub.4)-alkyl, which for its part may be substituted by hydroxyl, A and E represent bonds, D represents an oxygen atom, G represents doubly attached phenyl which are optionally substituted by one or more identical or different substituents selected from the group consisting of: hydroxyl, trifluoromethyl, carboxyl, fluorine, chlorine, bromine, (C.sub.1 -C.sub.3)-alkyl, hydroxy(C.sub.1 -C.sub.3)-alkyl or (C.sub.1 -C.sub.3)-alkoxy L represents a radical of the formula ##STR54## where the left-hand side of the radicals is attached to G, R.sup.2 represents (C.sub.1 -C.sub.8)-alkyl, which is optionally substituted by one or more identical or different substituents selected from the group consisting of: fluorine, chlorine, bromine, phenyl, trifluoromethyl or trifluoromethyl-substituted (C.sub.1 -C.sub.4)-alkoxy, and pharmaceutically acceptable salts thereof. 4. Compounds of the general formula (I), according to claim 1, in which R.sup.1 represents a radical of the formula ##STR55## A and E represent bonds, D represents an oxygen atom, G represents doubly attached phenyl, which is optionally substituted by fluorine, chlorine or bromine, L represents a radical of the formula ##STR56## where the left-hand side of the radical is attached to G, R.sup.2 represents (C.sub.1 -C.sub.4)-alkyl, which is optionally substituted by fluorine or trifluoromethyl, and pharmaceutically acceptable salts thereof. 5. The compound according to claim 1 ##STR57## 6. A process for preparing an arylsulphonamide according to claim 1, wherein [A] compounds of the general formula (II) are reacted with compounds of the general formula (III) in which R.sup.2 has the meaning given in claim 1, R.sup.43 represents halogen U represents a radical of the formula --SO.sub.2 --, --SO--, --CO--, --P(O)(OR.sup.37)-- or a single bond, in which R.sup.37 has the meaning given in claim 1, to give compounds of the general formula (Ia) in which R.sup.1, A, D, E, G, and R.sup.2 have the meaning given in claim 1, and M and U have the meaning given above, in inert solvents, or [B] compounds of the general formula (II) are initially reacted with trialkylsilyl chlorosulphonates, admixed with an acid and then reacted with a chlorinating agent, to give a compound of the general formula (IV) in which R.sup.1, A, D, E, and G have the meaning given in claim 1, and M has the meaning given above followed by reaction with compounds of the general formula (V) in which R.sup.2 has the meaning given in claim 1 and V represents oxygen or nitrogen, to give compounds of the general formula (Ib) in inert solvents in the presence of Bzl-NEt.sub.3.sup.+ Cl.sup.- and a base, or [C] compounds of the general formula (VI) are reacted with compounds of the general formula (VII) in which E, G and R.sup.2 have the meaning given in claim 1 and R.sup.44 represents a leaving group, to give compounds of the general formula (Ic) in which R.sup.1, A, D, E, G and R.sup.2 have the meaning given in claim 1, or [D] compounds of the geneial formula (Id) are reacted with chloroformate, and then with alcohols, to give compounds of the general formula (Ie) in which A, D, E, G, L and R.sup.2 have the meaning given in claim 1 and R.sup.47 represents radicals of the formulae ##STR59## or [E] compounds of the general formula (Ie) are reacted with (C.sub.1 -C.sub.6)-ketones or (C.sub.1 -C.sub.6)-aldehydes in the presence of a reducing agent, to give compounds of the general formula (If) in which A, D, E, G, L and R.sup.2 have the meaning given in claim 1 and R.sup.48 represents (C.sub.3 -C.sub.6)-alkenyl or (C.sub.1 -C.sub.6)-alkyl, or [F] compounds of the general formula (Ie) are reacted with compounds of the general formula (VIII) in inert solvents, to give compounds of the general formula (Ig) in which A, D, E, G, L and R.sup.2 have the meaning given in claim 1 and R.sup.50 represents a radical of the formula ##STR60## in which Q has the meaning given above, or [G] compounds of the general formula (Ih) ##STR61## in which A, D, E, G, L and R.sup.2 have the meaning given in claim 1, are converted by free-radical bromination, in an inert solvent into compounds of the general formula (Ii) ##STR62## in which A, D, E, G, L and R.sup.2 have the meaning given in claim 1, and one of the substituents W or X represents bromine and the other represents hydrogen, and subsequently reacted with compounds of the general formula (IX) in which R.sup.51 represents (C.sub.1 -C.sub.6)-alkyl and in inert solvents, to give compounds of the general formula (Ij) to give compounds of the general formula (X) ##STR64## in which A, D, F, G, L, and R.sup.2 have the meaning given in claim 1, and W and R.sup.51 have the meaning given above, and finally reduced to the methylhydroxy function, or [H] in the case that R.sup.1 represents the rings listed in claim 1, which are substituted by the radical of the formula ##STR65## in which c, T, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 have the meaning given in claim 1, compounds of the general formula (XI) are reacted with compounds of the general formula (XII) ##STR66## in which T has the meaning given in claim 1, R.sup.11' represents hydrogen and R.sup.12' represents one of the amino protective groups listed above, in inert solvents, and the amino protective group is cleaved off, and, in the last step, a reduction with BH.sub.3 xS(CH.sub.3).sub.2 in tetrahydrofuran is carried out, and, in the case of the pure enantiomers, an HPLC separation is carried out, and, in the case that D=--SO-- or --SO.sub.2 --, an oxidation is carried out on the corresponding amines. 7. A pharmaceutical composition which comprises, as an active component, at least one compound according to claim 1 in combination with at least one pharmaceutically acceptable non-toxic vehicle or excipient. 8. A method for the treatment of neurodegenerative disorders comprising administering to a mammal an effective amount of a compound according to claim 1. 9. A method for the treatment of cerebral ischaemias and craniocerebral trauma comprising administering to a mammal an effective amount of a compound according to claim 1. 10. A method for the treatment of pain, emesis, nausea, glaucoma, asthma, anorexia, convulsions, rheumatism, sedation, and mobility disorders comprising administering to a mammal an effective amount of a compound according to claim 1. 11. A method for the treatment of bacterial or viral infections, autoimmune diseases, inflammatory or autoimmunologically related diseases of the joints of the bone and muscle apparatus, of the internal organs, of the central nervous system, of the sense organs and of the haematogenic system comprising administering to a mammal an effective amount of a compound according to claim 1. 12. A method for the treatment of migraine and spasticity comprising administering to a mammal an effective amount of a compound according to claim 1. 13. The process of claim 6, wherein said trialkysilyl chlorosulphonate is trimethylsilyl chlorosulphonate and said chlorinating agent is phosphorus pentachloride. 14. The process of claim 6, wherein R.sup.44 is selected from the group consisting of fluorine, chlorine, and bromine. 15. The process of claim 6, wherein said chloroformate is selected from the group consisting of 1-(1-chloro)ethyl chloroformate and methyl chloroformate. 16. The process of claim 6, wherein said reducing agent is sodium cyanoborohydrate. 17. The process of claim 6, wherein R.sup.49 is a halogen. 18. The process of claim 6, wherein said free-radical bromination is performed using N-bromosuccinimide. 19. The process of claim 6, wherein R.sup.12' is tert-butyloxycarbonyl. 20. The process of claim 6, wherein, after removal of the amino protective group, the amino group is reductively alkylated or dialkylated with an aldehyde, ketone, or halide. 